Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | ACR | P10323 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772842 | 0.90 | KCNK3 (0.46) | LMNAMAPTKDM4EMAPK1KCNK3 | |
| SCHEMBL6775462 | 0.90 | KIF11 (0.39) | PLGPLAUPLATRXFP1POLB | |
| SCHEMBL6776008 | 0.89 | MAP4K4 (0.38) | PLGPLAUPLATKDM4EMAPK1 | |
| SCHEMBL6775914 | 0.89 | KIF11 (0.37) | PLGPLAUPLATKIF11ACR | |
| SCHEMBL6781865 | 0.88 | MAP2K4 (0.39) | PLGPLAUPLATKIF11P2RY14 | |
| SCHEMBL6770619 | 0.84 | PARP1 (0.35) | PLGPLAUPLATRXFP1DDR2 | |
| SCHEMBL6271457 | 0.83 | PLG (0.43) | PLGPLAUPLATLMNAMAPT | |
| SCHEMBL6775800 | 0.83 | MAPT (0.38) | MAPTKDM4E | |
| SCHEMBL6777730 | 0.83 | OPRM1 (0.40) | LMNAMAPTKIF11 | |
| SCHEMBL31337247 | 0.83 | CHEK2 (0.36) | PLGPLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | claimed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | claimed |
| EP-0977741-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047879-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-10-29 | — | — | WO | claimed |
| US-6696475-B2 | N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS | NEUROSEARCH A/S (DK) | 2004-02-24 | — | — | US | disclosed |
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | disclosed |
| EP-0977741-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047879-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNH2, KCNJ2 | PLG 3128/4885PLAU 4624/4885PLAT 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.